Human cystic and alveolar echinococcosis (Hydatid disease) is still cause of morbidity andmortality in some parts of the world including Eastern Asia, Middle East, Europe Northand South America. Somehow it is a public health problem in the Mediterranean andMiddle East area (1, 2). Hydatid disease is a chronic parasitic disease with animal-humancycle. It is caused by dog tapeworm belonging to the genus Echinococcus (Taeniidae); thelarval (metacastode) stages. There are three recognized forms of echinococcosis: Cysticcaused by E granulosus, Alveolar caused by E multilocularis, and Polycystic caused by Evogeli (3). Among three forms of Hydatid disease, alveolar echinococcosis is associatedwith poor response and cyst rupture is an expected probability which complicatesmanaging patient and treatment (4, 5). Despite of current control methods, eliminationof this pathogen is difficult. Hydatid control campaigns have made impressive technological improvements in the prevention, diagnosis and treatment of human and animal cystic echinococcosis. Although using of these new methods increased the efficiency of hydatid control programs but hydatid disease is still common, the treatment is hard enough and it will be more complex when we face a ruptured hydatid cyst (2). Human cystic echinococcosis is the most common presentation which estimated to be more than 95% of whole global cases (2-3 milion) compared to alveolar echinococcosis which is less than 0.5 milion cases (all reported in northen hemisphere). Lungs are involved in about 30% of cystic echinococcosis (2). The main way to diagnose human echinococcosis is imaging techniques (eg computed tomography, magnetic resonance imaging, ultrasound and radiography) which can detect space occupying lesions well. Laboratory-based techniques is the other useful way for confirmation of clinical infection by the aid of specific serum antibodies (IgG antibodies and recombinant antigen B subunits) (1, 2). In cystic echinococcosis, fluid-filled cysts develop and grow in the some potential body cavities mainly in liver and lungs or other locations. Cystic larvae grows slowly, thus it is tolerated well by the host. In return, alveolar echinococcosis invades the surrounding parenchyma and does not have well-defined external margins (4, 5). Its treatment is difficult because most cystic lesions develop in the lung in short while. Therefore surgical removal is the principal therapeutic approach to treat ruptured and chronic pulmonary hydatid cysts but on the other side medicosurgical approaches are expanding, along with percutaneous drainage for hepatic cystic echinococcosis (3-5). Generally these patients outlook is unclear and rarely predictable, so long-term imaging follow-ups seems to be essential to manage their condition and achieving favorable treatment outcomes (6).This paper mainly focuses on patients with ruptured pulmonary Echinococcus granulosus infections (Alveolar Hydatid Disease), those whom suffered from rupture alveolar Hydatid cyst. In this study we aimed to remove these ruptured pulmonary Hydatid cysts by aid of Bronchoscope Saline Injection Method (M.E. Hejazi method).